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Cystinosis is a disorder associated with excessive lysosomal cystine accumulation secondary to defective cystine efflux. Patients affected
by this disease develop a variable degree of symptoms depending on the involved tissues. Accumulation of cystine in myocardium may lead
to heart failure. However, the mechanisms by which cystine is toxic to the tissues are not fully understood. Considering that thiolic enzymes
like pyruvate kinase (PK) may be altered by disulfides like cystine, the main objective of the present study was to investigate the effect of
cystine on PK activity in the heart of developing rats. We performed kinetic studies and investigated the effects of reduced glutathione (GSH),
a biologically occurring thiol groups protector, and cysteamine, the drug used for cystinosis treatment, on the enzyme activity. We observed
that cystine inhibited the enzyme activity non-competitively in a dose- and time-dependent way. We also observed that GSH and cysteamine
fully prevented and reversed the inhibition caused by cystine, suggesting that cystine inhibits PK activity by oxidation of the sulfhydryl
groups of the enzyme. Although there is no definite proof of cystine within cytoplasm, there is indirect proof t it is able to escape lysosomes
and come in contact with PK. Considering that cysteamine is used in patients with cystinosis because it causes parenchymal organ cystine
depletion, the present data provide a possible new effect for this drug.
D 2004 Elsevier B.V. All rights reserved.Keywords: Cystinosis; Cystine; Cysteamine; Pyruvate kinase; Heart1. Introduction
Cystinosis is an autosomal recessive disorder associated
with excessive lysosomal cystine accumulation secondary to
defective lysosomal cystine efflux [1,2]. The causative gene
(CTNS) encodes cystinosin, an integral membrane protein
thought to be a H+-driven lysosomal transporter, responsible
for cystine transport out of lysosomes [3]. The most common
form of cystinosis, the nephropathic or infantile type, is
characterized by renal failure in second decade of life unless
treated by cysteamine and other systemic complications [4].
Patients affected by this disease accumulate cystine in most
tissues developing a variable degree of symptoms depending
of the involved tissues. The treatment must be initiated in the
first 2 years of age with the aminothiol cysteamina (2-
mercaptoethylamine), which causes parenchyimal organ cys-0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: clovisdw@ufrgs.br (C.M.D. Wannmacher).tine depletion [5]. If started early, this treatment can prevent
the spontaneous evolution towards end stage renal disease
between 6 and 12 years of age [6]. Surviving adult patients
may develop involvement of skeletal muscle [7], myocardi-
um [8], and heart failure due to restrictive cardiomyopathy
associated with 1000-fold higher tissue cystine content [9].
The mechanisms by which cystine is toxic to the tissues
are not fully understood. However, it is well known that
some enzymes activity may be altered by thiol/disulfide
exchange between protein sulfhydryl groups and biologi-
cally occurring disulfides [10,11]. Considering that cystine
is a disulfide, it is possible that it may act on intracellular
thiol-enzymes, modifying cell function [11].
Pyruvate kinase, a cytosolic thiol-enzyme present in all
tissues, is crucial for the glycolysis pathway. There are at
least four known isozymic forms of PK in vertebrates,
designated as L (liver), M1 (brain and muscle), M2 (undif-
ferentiated and proliferating tissues) and R (kidney). These
isozymes differ in their chemical, physical, kinetic, electro-
phoretic and immunological properties, as well as their
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purified from bovine [13] and pig [14] heart indicate that
M2 and M1 isozymes are produced from the same gene by
alternative splicing [15] and that M2 is progressively
replaced by M1 in skeletal muscle, heart and brain during
development [16]. M1 isozyme presents a tetrametric struc-
ture, hyperbolic kinetics, and thiol groups necessary for
functioning [17]. Therefore, considering that PK is a thiol-
enzyme, and cystine is a biologically occurring disulfide, the
main objective of the present study was to investigate the
effect of cystine on PK activity in the heart of developing
rats. In an attempt to better characterize the inhibition cystine
caused in PK activity, we also performed kinetic studies and
investigated the effects of reduced glutathione (GSH), a thiol
group protector, and cysteamine, on the enzyme activity.Fig. 1. Effect of cystine concentration on pyruvate kinase activity in
mitochondria-free homogenates from rat heart. Pyruvate kinase activity is
expressed as Amol pyruvate formed/min/mg protein. Data are meanF S.D.
of six independent experiments performed in triplicate. *P < 0.05;
**P < 0.01; ***P < 0.001 compared to controls (Tukey test).2. Materials and methods
2.1. Animals and reagents
Twenty-one-day-old Wistar rats bred in the Department
of Biochemistry, UFRGS, were used in the experiments.
Rats were kept with dams until they were sacrificed. The
dams had free access to water and to a standard commercial
chow (Germani, Porto Alegre, RS, Brazil) containing 20.5%
protein (predominantly soybean supplemented with methi-
onine), 54% carbohydrate, 4.5% fiber, 4% lipids, 7% ash
and 10% moisture. Temperature was maintained at 24F 1
jC, with a 12:12 h light–dark cycle. The ‘‘Principles of
Laboratory Animal Care’’ (NIH publication 85–23, revised
1985) were followed in all the experiments, and the exper-
imental protocol was approved by the Ethics Committee For
Animal Research of the Federal University of Rio Grande
do Sul. All chemicals were purchased from Sigma Chem-
ical, St Louis, MO, USA.
2.2. Preparation of heart tissue
Forty animals were killed by decapitation and the heart
was removed and immediately placed on an ice-cooled glass
plate. Time elapsed between decapitation and dissection was
less than 1min. After dissection, the heart was washed in SET
buffer (0.32 M sucrose/1 mM EGTA/10 mM Tris–HCl, pH
7.4), minced finely and homogenized in the same SET buffer
[1: 20 (w/v)] with a Potter–Elvehjem glass homogenizer. The
homogenate was centrifuged at 10,000g for 15 min at 4 jC
in a Sorval refrigerate centrifuge. The pellet was discarded
and the mitochondria-free supernatant was used for the
determination of protein concentration and enzyme assays.
2.3. Protein determination
The protein content of the mitochondria-free heart homo-
genates was determined by the method of Lowry et al. [18]
using bovine serum albumin as the standard.2.4. Enzyme assay
Pyruvate kinase activity was assayed essentially as de-
scribed by Leong et al. [19]. The incubation medium
consisted of 0.1 M Tris–HCl buffer, pH 7.5, 10 mM MgCl2,
0.16 mM NADH, 75 mM KCl, 5.0 mM ADP, 7 units of L-
lactate dehydrogenase, 0.1% (v/v) Triton X-100, and 20 Al of
the mitochondria-free supernatant in a final volume of 0.5
ml. Unless otherwise stated, the reaction was started after 30
min of pre-incubation by the addition of 1 mM phospho-
enolpyruvate (PEP). All assays were performed in triplicate
at 25 jC. Reagents concentration and incubation time (2
min) were chosen to assure the linearity of the reaction.
Results were expressed as Amol pyruvate formed/min/mg
protein. Tests performed in our laboratory indicated that the
substances added to the incubations did not interfere with
LDH activity or with spectrophotometric readings (results
not shown). Unless otherwise stated, cystine and the other
substances were dissolved in the same buffer solution before
addition to the assay.
The experiments were performed in the following
sequence:
1. Cystine was added to the incubation medium at 1, 2.5, and
5 mM final concentrations and pre-incubated for 30 min.
2. Cystine was added to the incubation medium at 2, 4, and
6 mM final concentrations and pre-incubated for 0, 30,
60, or 90 min.
3. Cystine was added to the incubationmedium at 4mM final
concentration and pre-incubated for 0, 60, or 90 min; 1
mM GSH was added before or after pre-incubation.
4. Cystine was added to the incubationmedium at 4mM final
concentration and pre-incubated for 0, 60, or 90 min; 1
mM cysteamine was added before or after pre-incubation.
5. Competition studies between cystine and the enzyme
substrates PEP and ADP were performed according to
Lineweaver–Burk [20]. In these experiments, PEP and
ADP concentrations were chosen to assure linearity of
pyruvate kinase activity and of cystine inhibition.
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Fig. 2. Effect of pre-incubation time at different cystine concentrations on
pyruvate kinase activity in mitochondria-free homogenates from rat heart.
Pyruvate kinase activity is expressed as Amol pyruvate formed/min/mg
protein. Data are meanF S.D. of six independent experiments performed in
Fig. 4. Effect of reduced glutathione (GSH) added before or after 60 min of
pre-incubation of pyruvate kinase with cystine in mitochondria-free
homogenates from rat heart. Pyruvate kinase activity is expressed as Amol
mol pyruvate formed/min/mg protein. Data are meanF S.D. of six
independent experiments performed in triplicate. **P < 0.01 compared to
the other groups (Tukey test).
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Data were analyzed by one-way ANOVA or multivariate
analysis followed by the Tukey test when the F values were
significant. Linear regression was used to evaluate dose or
time response. All data were analyzed by the Statistical
Package for Social Sciences inserted in an IBM-compatible
PC computer.
triplicate. *P < 0.05; **P < 0.01 compared to controls (Tukey test).3. Results
First, cystine was added to the incubation medium at 1,
2.5, and 5 mM final concentrations and pre-incubated for 30
min. The results showed that cystine inhibited PK activity inFig. 3. Effect of reduced glutathione (GSH) on the inhibiton caused by
cystine at different pre-incubation times on pyruvate kinase activity in
mitochondria-free homogenates from rat heart. Pyruvate kinase activity is
expressed as Amol pyruvate formed/min/mg protein. Data are meanF S.D.
of six independent experiments performed in triplicate. **P < 0.01
compared to controls (Tukey test).all tested concentrations in a dose-dependent way [F(1,22) =
96.49; P < 0.0001; h = 0.91; t= 9.82; P < 0.0001] (Fig. 1).
Since L-phenylalanine is a known inhibitor of PKM (M1 and
M2) activity, and L-alanine reverses the inhibition caused by
L-phenylalanine by competition [21], we investigated the in
vitro effect of 4 or 8 mM L-alanine addition together with 4
mM cystine on the enzyme activity. Our results showed that
cystine inhibited PK activity [F(5,18) = 110.84; P < 0.0001],
whereas L-alanine did not prevent the PK inhibition caused by
cystine (control = 1.31F 0.06; 4 mM L-alanine = 1.45F
0.13; 4 mM cystine = 0.55F 0.05; 4 mM L-alanine + 4 mM
cystine = 0.46F 0.02; 8 mM L-alanine = 1.41F 0.09; 8 mM
L-alanine + 4mMcystine = 0.57F 0.12 Amol/min/mg protein
for four independent experiments).
Next, the mitochondria-free homogenate was pre-incubat-
ed with 2, 4, and 6 mM of cystine for 0, 30, 60, or 90 min.
Cystine inhibited PK activity in a time-dependent way at all
tested concentrations: 2 mM [F(1,22) = 55.28; b = 0.84;
P < 0.0001] ; 4 mM [ F (1 ,22) = 87.05; b =  0.89;
P < 0.0001]; 6 mM [ F(1,22) = 111.98; b =  0.91;
P < 0.0001]. Cystine did not altered PK activity withoutFig. 5. Effect of cysteamine (cysN) added before or after 60 min of pre-
incubation of pyruvate kinase with cystine in mitochondria-free homoge-
nates from rat heart. Pyruvate kinase activity is expressed as Amol pyruvate
formed/min/mg protein. Data are meanF S.D. of six independent experi-
ments performed in triplicate. **P < 0.01 compared to controls (Tukey test).
Fig. 6. Lineweaver–Burk plot for pyruvate kinase activity with respect to adenosine-5V-diphosphate (ADP) at various concentrations of cystine. Pyruvate kinase
activity is expressed as Amol pyruvate formed/min/mg protein. Pyruvate kinase activity was measured after 60 min of pre-incubation. Data are representative of
at least three independent experiments performed in triplicate.
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inhibited the enzyme activity in a dose-dependent way when
pre-incubated for 30 min [F(1,22) = 36.83; b = 0.79; P <
0.0001]; 60 min [F(1,22) = 122.55; b = 0.92; P < 0.0001];
or 90 min [F(1,22) = 91.24; b = 0.90; P < 0.0001] (Fig. 2).
Next, we investigated the effect of 4 mM cystine in the
presence of 1 mM GSH at 0, 60 and 90 min pre-incubation.
Multivariate analysis between subjects showed that 4 mM
cystine inhibited PK activity along time [F(2,15) = 33.32;
P < 0.001], whereas 1 mM GSH did not alter PK activity
along pre-incubation time [F(2,15) = 1,51; P>0.25], butFig. 7. Lineweaver–Burk plot for pyruvate kinase activity with respect to phosph
activity is expressed as Amol pyruvate formed/min/mg protein. Pyruvate kinase acti
at least three independent experiments performed in triplicate.fully prevented the inhibition caused by cystine [F(2,
15) = 0.99; P>0,39 (Fig. 3). We also investigated whether
the inhibition caused by cystine on PK activity was revers-
ible or not. Cystine inhibited PK activity [F(5,30) = 11.71;
P < 0.001] and the addition of 1 mM GSH after 60 min of
pre-incubation with 4 mM cystine reversed the inhibition of
the enzyme activity (Fig. 4). Considering that GSH is a
strong physiological protector of thiol groups, these results
suggest that cystine inhibited PK activity by acting on
essential sulfhydryl groups of the enzyme. However, deter-
mination of sulfhydryl groups before and after exposure ofoenolpyruvate (PEP) at various concentrations of cystine. Pyruvate kinase
vity was measured after 60 min of pre-incubation. Data are representative of
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hypothesis.
Considering that cysteamine is a thiol-compound like
GSH, we also investigated its effect on the inhibition caused
by cystine. As can be seen in Fig. 5, 4 mM cystine inhibited
PK activity [F(5,30) = 20.42; P < 0.001] and 1 mM cyste-
amine fully prevented this inhibition when added before the
pre-incubation and reversed the inhibition when added after
60 min of pre-incubation.
In an attempt to better characterize the inhibition of PK
activity caused by cystine, competition studies between
cystine and the enzyme substrates ADP and PEP were
performed at 60 min of pre-incubation, according to Line-
weaver–Burk. The double-reciprocal plots showed that the
inhibition caused by cystine on PK activity was of the
noncompetitive type for the two substrates, reinforcing the
results obtained with GSH and cysteamine (Figs. 6 and 7).4. Discussion
Cystinosis is caused by a severe deficiency of CTNS
gene, resulting in defective activity of cystinosin, a protein
responsible for the transport of cystine out of lysosomes [3].
Although tissue damage might depend on cystine accumu-
lation in the affected tissues, the mechanisms by which
cystine leads to cell and tissue damage are still obscures.
Considering that cystine could alter the activity of thiol-
enzymes [11], we performed studies on the effect of this
amino acid on PK activity, a crucial thiol-enzyme for energy
production in all mammalian tissues.
In the present study, we first investigated the effects of
cystine at different times of pre-incubation on the activity of
PK in the heart from developing rats. We observed that
cystine inhibited the enzyme activity in a dose- and time-
dependent way. Next, we investigated the effect of GSH, a
naturally occurring thiol group protector, on the inhibition
caused by cystine. We observed that the inhibition cystine
caused in PK was fully prevented and reversed by GSH,
suggesting that cystine inhibits PK activity possibly by
oxidation of the sulfhydryl groups of the enzyme. However,
studies to confirm the alteration of sulfhydryl groups before
and after exposure to cystine need to be done to confirm this
hypothesis. In order to better characterize the enzyme
inhibition, we performed kinetic competition studies be-
tween cystine and the two enzyme substrates PEP and ADP.
The Lineweaver–Burk plot indicated that the inhibition
caused by cystine on PK activity was of the noncompetitive
type in relation to ADP and PEP, reinforcing the hypothesis
of progressive oxidation of the thiol groups of the enzyme
by cystine. Ki values for cystine inhibition were 2 10 3
and 1.3 10 3 M for ADP and PEP as substrate, respec-
tively. Ki values are far from cystine concentration (18.5
nmol/mg wet tissue, or around 30 10 3 M considering
approximately 60% water in the tissue) found in the
myocardium of a patient with cystinosis [9]. Consideringthat Ki is the equilibrium constant for inhibitor binding, our
results indicate that cystine might exert a strong inhibition of
PK activity, reducing energy production.
Next, we tested the effect of cysteamine, a thiol-com-
pound used in the treatment of cystinosis. We observed that
cysteamine prevented and reversed the inhibition cysteine
caused in PK activity.
PK catalysis is a crucial step in the glycolytic pathway,
an important route that provides energy for cardiac muscle
function. Studies on rabbit muscle pyruvate kinase demon-
strated that each of the four enzyme subunits contains a
sulfhydryl group essential for catalytic activity [22]. Oga-
sawara et al. [23] have demonstrated that PK isozyme from
rat liver is inhibited by cystine in vitro. Now, we demon-
strate that cystine inhibits PK isozyme from cardiac muscle
in a noncompetitive manner, possibly by oxidating thiol
groups of the enzyme. Time and dose dependence of PK
inhibition by cystine indicate a sequential oxidation of the
four sulfhydryl groups of the enzyme. We also demonstrate
that GSH and cysteamine can prevent and reverse this
inhibition. Our kinetic results showing that cystine causes
a reversible alteration in maximal velocity but not in Km
indicate that the active site of the enzyme was not altered,
suggesting an oxidation of thiol groups of the enzyme not
directly involved in catalysis.
Patients affected by cystinosis may accumulate cystine in
cardiac muscle and develop a variable degree of cardiac
dysfunction, whose pathophysiology is still unclear [8,9].
Cystine accumulation is considered the main responsible by
tissue damage in this disease, but the mechanisms of toxicity
remain to be investigated. The inhibition caused by cystine
on PK activity might be one of such mechanisms.
Cystine is usually considered to be completely isolated
from the cytosol within lysosomes. However, it is possible
that the small cystine crystals may partially disrupt the
lysosomal membranes, since positive reaction for acid
phosphatase was found to be localized at the periphery of
the cystine crystals only in some of them [24]. Besides,
ultrastructural observations in the liver and in the kidney of
cystinotic patients, and in biopsies of renal allografts from
patients with cystinosis showed cystine accumulation in the
cytoplasm, nucleus and cytoplasmic inclusions of dark cells,
and also extracellularly, indicating that cystine storage may
not be limited to lysosomes [25,26]. On the other hand,
renal tubule cells of rats loaded with cystine developed
Fanconi’s syndrome secondary to a decrease in energy
generation [27,28]. Therefore, it is conceivable that PK, a
cytosolic enzyme, could be inhibited in patients affected by
cystinosis.
Deficient activities of several thiol enzymes, but not of
non-thiol enzymes, in postmortem liver and kidney tissue
from patients with nephropathic cystinosis were early
reported [29]. However, these enzymes could have normal
activities in the intact cells and be inhibited by cystine
following lysis of the cells and partial release of the
compartmentalized cystine [30]. Considering that lysosome
T.G. Rosa et al. / Biochimica et Biophysica Acta 1689 (2004) 114–119 119rupture with cell death cannot explain the Fanconi Syn-
drome in cystinosis, because patiens with acute and chronic
renal failure do not present this syndrome, it is important to
investigate other mechanisms for cell dysfunction in cysti-
nosis. Inhibition of thiol enzymes like PK could be one of
such mechanisms.
Considering that cysteamine is used in patients with
cystinosis because it causes parenchymal organ cystine
depletion, the present data provide a possible new effect
for this drug, since the protective effect of cysteamine could
be important in preventing and reversing some metabolic
consequences of cystine accumulation on PK activity.
Further studies are necessary to evaluate PK activity in
patients affected by cystinosis.Acknowledgements
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